Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Venous Thrombosis III: Interprofessional Care

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

Extrinsic and Intrinsic Pathways of Hemostasis

Extrinsic and Intrinsic Pathways of Hemostasis

Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...

Clot Retraction and Fibrinolysis

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.

Coagulation

Coagulation

The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Point-of-care ultrasound tele-didactic teaching for prehospital emergency personnel (POCUS TT study): a randomized non-inferiority trial.

BMC medical education·2026

Same author

Association of surgeon sex with postoperative adverse outcomes in adult cardiac surgery: a nationwide cohort study.

Journal of cardiothoracic surgery·2026

Same author

First attempt success rate of intraosseous access in preterm infants and neonates: a systematic review.

Resuscitation plus·2026

Same author

A serious video game for teaching basic point-of-care echocardiography skills: a non-inferiority trial.

BMC medical education·2026

Same author

Surgical repair of Tetralogy of Fallot - Long-term outcomes into the second decade after transannular patch repair and annulus-sparing patch repair.

International journal of cardiology. Congenital heart disease·2026

Same author

The incidence of early recurrent venous thromboembolism: a systematic review and meta-analysis.

Research and practice in thrombosis and haemostasis·2026

Search research articles

Related Experiment Video

Updated: Jun 11, 2026

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

Published on: February 27, 2026

ProCGlobal and endogenous thrombin potential during pregnancy.

Gregor Hron¹, Paul A Kyrle, Alexandra Kaider

¹Division of Hematology and Hemostasis, Department of Medicine I, Medical University of Vienna, Währinger Gürtel 18-20, Vienna, Austria.

American Journal of Obstetrics and Gynecology

|July 6, 2010

Summary

Pregnancy increases blood clot risk. Low-molecular-weight heparin prophylaxis did not fully normalize coagulation markers, ProCGlobal and endogenous thrombin potential (ETP), in pregnant women.

More Related Videos

RNA-seq Analysis of Transcriptomes in Thrombin-treated and Control Human Pulmonary Microvascular Endothelial Cells

RNA-seq Analysis of Transcriptomes in Thrombin-treated and Control Human Pulmonary Microvascular Endothelial Cells

Published on: February 13, 2013

Related Experiment Videos

Last Updated: Jun 11, 2026

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

Published on: February 27, 2026

RNA-seq Analysis of Transcriptomes in Thrombin-treated and Control Human Pulmonary Microvascular Endothelial Cells

RNA-seq Analysis of Transcriptomes in Thrombin-treated and Control Human Pulmonary Microvascular Endothelial Cells

Published on: February 13, 2013

Area of Science:

Obstetrics and Gynecology
Hematology
Thrombosis Research

Background:

Pregnancy is a natural state of increased blood clotting risk (hypercoagulability).
Assessing coagulation activation is crucial for managing thrombotic risk during pregnancy.

Purpose of the Study:

To evaluate global coagulation activation markers, ProCGlobal and endogenous thrombin potential (ETP), in pregnant women.
To compare these markers in women receiving low-molecular-weight (LMW) heparin prophylaxis versus those without.

Main Methods:

Prospective study of 113 healthy pregnant women and 61 women on LMW heparin prophylaxis.
Measurement of ProCGlobal and ETP in venous blood across three trimesters of pregnancy.

Main Results:

ProCGlobal levels significantly decreased throughout pregnancy in all participants.
ETP levels remained stable until the third trimester, then decreased.
Anticoagulated women showed lower ProCGlobal and higher ETP levels compared to healthy controls.

Conclusions:

ProCGlobal decreases as pregnancy progresses.
Significant coagulation activation persists in high-risk pregnant women on LMW heparin, indicated by low ProCGlobal and high ETP.